John Canepa has been Candel’s Chief Financial Officer Since December 2020. Mr. Canepa has over 40 years of experience in the life science industry as an audit partner with a large international public accounting firm, and as a financial executive with public and private life science companies. Prior to joining Candel, he served as CFO of Frequency Therapeutics from December 2018 until December 2020. During this time, Frequency completed several public and private financings, including its initial public offering in October 2019, and dramatically expanded its operations. Prior to joining Frequency, he served as CFO of Agilis Pharmaceuticals, Inc. and was instrumental in its sale to PTC Therapeutics in August 2018. Prior to Agilis, he was COO and CFO of Asterand Bioscience and led its sale to a private equity group in 2017. Mr. Canepa began his career at Arthur Andersen & Co. and was with the firm for 23 years. He was a partner in the Boston office technology practice and the worldwide leader of the firm’s life science practice.
Mr. Canepa received a BA in economics from Denison University and a master’s degree in finance from Michigan State University. John is a Trustee of Mount Auburn Hospital in Cambridge Massachusetts, where he currently serves as co-chair of the board of trustees and is on the board of the Beth Israel Lahey Health network.